NERO – Nausea/Emesis Registry in Oncology

As patients still consider CINV as one of the most distressing side effects of chemotherapy, the potential to improve patient´s quality of life is still there. The best suited supportive care to the patient can improve not only the quality of life of the patient, but also, in long term, the response to anticancer treatment and patients´ survival. Initiation of such a registry could also increase the awareness and experience of supportive care in cancer patients by oncologists and nurses.

Primary objective of the project:

• to estimate the impact of the adherence to antiemetic guidelines in cancer patients undergoing repeated cycles of either MEC or HEC regimens in Eastern Europe, measured by complete response during 120 h after chemotherapy

Secondary objectives of the project:

• to evaluate the impact of CINV on the quality of life in cancer patients receiving MEC/HEC

Other important information:

• Expert guarantor: Professor Matti Aapro, MD (Multidisciplinary Institute of Oncology, Clinique de Genolier, Switzerland)
• Partners: nearly 80 clinical sites from 7 European countries: Austria, Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia (you can find more detailed information on the website of the NERO project)